Research & Development Mekonos closes $25M funding round for cell therapy platform

Mekonos closes $25M funding round for cell therapy platform

-

Mekonos closes funding of $25M in a series a round as it develops the future of cell therapies on a chip. The Biotech Company has developed a platform that is able to support the multiple delivery of cell payloads right down to the cell level, and allows for the physical delivery of these payloads.

Biotech Startup Mekonos raises oversubscribed $25 million after prominent research labs had promising results for the company’s developed platform for chip technology. The delivery system for the payload will be ex-vivo.

As Mekonos closes funding it has revealed plans for the use of this acquired capital. The company is planning to venture into business development, Microfluidics, MEMS among other areas.

The future of cell therapies on a chip shows the excellent ability to provide repeated and measured doses, such as CRISPR, into vulnerable cell types that include stem cells.

With this latest funding, Mekonos plans to bring change to cell therapy, an area that has not witnessed innovation in over two decades. Mekonos official stated that they are keen on disrupting existing technology in cell engineering and are making an effort to delve into personalized medicine on a large scale.

Latest news

Patient-Centric Clinical Trials And The Role Of A Travel Concierge

Many people find booking plane tickets, arranging road transportation and overnight lodging overwhelming. Add into that mix...

China forces insulin price cuts resulting in pullback for global pharma players

Xinhua, a Chinese news channel, commented on the price cut on insulin which was brought on by...

Aussie pharma CSL in talks to buy Swiss firm Vifor Pharma for USD 7B

CSL, the Australian giant, is in talks to buy Vifor Pharma in a deal that is valued...
- Advertisement -

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

Amgen’s KRAS drug gets early FDA approval for lung cancer with specific mutation

On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC

You might also likeRELATED
Recommended to you